H.R. 7635 · 119th Congress · Foreign Trade and International Finance

CHARGE Act

In committee602 words Introduced Feb 20, 2026 · Latest action Feb 20, 2026

How far it has goneStage 2 of 6
  1. IntroducedFeb 20, 2026 Done
  2. CommitteeReferred to Ways and Means Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

1 organization · 3 filings · Q1 2026–Q3 2026

See which of this bill’s sponsors and cosponsors got money from Bristol-Myers Squibb Company’s PAC → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Bristol-Myers Squibb Company 3 of 3 quarters
    “Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act”

    $7.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing

Organizations that named H.R. 7635 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Feb 20, 2026Referred to the House Committee on Ways and Means.
  2. Feb 20, 2026Introduced in House